Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00422 ...
Drug Name Methylphenidate
Molecular Weight 233.3062
Molecular Formula C14H19NO2
CAS Number 113-45-1
SMILES COC(=O)C(C1CCCCN1)C1=CC=CC=C1
External Links
DRUGBANK DB00422
T3DB T3D2786
PubChem Compound 4158
PDR 1003
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Water Solubility 1255.0 mg/L 1255 mg/L DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Reference
AUC 86.0 ng.h/ml 50.4-121.5 ng.h/ml Children; Drug form; DRUGBANK
Bioavailability 30.0 % 30(11-52) % Tablet, PO, oral; immediate release formulation; Drug form; DRUGBANK
Bioavailability 22.0 % 22±8 % PO, oral; Raceme D; The Pharmacological Basis of Therapeutics
Bioavailability 5.0 % 5±3 % PO, oral; Raceme L; The Pharmacological Basis of Therapeutics
C Max 10.5 ng/ml 6-15 ng/ml Children; Drug form; DRUGBANK
C Max 7.8 ng/ml 7.8 ng/ml PO, oral; Children; Drug form; DRUGBANK
C Max 10.8 ng/ml 10.8 ng/ml PO, oral; adults; Drug form; DRUGBANK
C Max 18.0 ng/ml 18±4.3 ng/ml Oral single dose; Raceme D; The Pharmacological Basis of Therapeutics
C Max 3.0 ng/ml 3.0±0.9 ng/ml Oral single dose; Raceme L; The Pharmacological Basis of Therapeutics
T Max 8.0 h 6-10 h PO, oral; Drug form; DRUGBANK
T Max 8.8 h 8.1-9.4 h Children; Drug form; DRUGBANK
T Max 2.0 h 1-3 h PO, oral; Drug form; DRUGBANK
T Max 2.4 h 2.4±0.8 h Oral single dose; Raceme D; The Pharmacological Basis of Therapeutics
T Max 2.1 h 2.1±0.6 h Oral single dose; Raceme L; The Pharmacological Basis of Therapeutics
Clearance 10.2 L/h/kg 10.2 L/h/kg Average clearance; PO, oral; Children; adults; DRUGBANK
Clearance 0.57 L/h/kg 0.565 L/h/kg Average clearance; intravenous injection, IV; normal,healthy; adults; DRUGBANK
Clearance 0.40 L/h/kg 6.7±2.0 ml/min/kg normal,healthy; adults; Male, men; The Pharmacological Basis of Therapeutics
Clearance 0.72 L/h/kg 12±4.7 ml/min/kg normal,healthy; adults; Male, men; The Pharmacological Basis of Therapeutics
Clearance 0.57 L/h/kg 9.42 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 20.0 L/kg ~20 L/kg Apparent volume of distribution; Children; DRUGBANK
Volume of Distribution 2.2 L/kg 2.23 L/kg intravenous injection, IV; normal,healthy; adults; DRUGBANK
Volume of Distribution 2.7 L/kg 2.7±1.1 L/kg normal,healthy; adults; Male, men; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.8 L/kg 1.8±0.9 L/kg normal,healthy; adults; Male, men; The Pharmacological Basis of Therapeutics
Volume of Distribution 2.2 L/kg 2.2 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 3.5 h ~3.5 h adults; DRUGBANK
Half-life 2.4 h 2.4 h elimination half-life; Children; DRUGBANK
Half-life 2.1 h 2.1 h elimination half-life; adults; DRUGBANK
Half-life 2.4 h 2.4 h elimination half-life; Children; immediate release formulation; DRUGBANK
Half-life 2.1 h 2.1 h elimination half-life; adults; immediate release formulation; DRUGBANK
Half-life 6.0 h 6.0±1.7 h Raceme D; The Pharmacological Basis of Therapeutics
Half-life 2.2 h 2.2 h The Pharmacological Basis of Therapeutics
Half-life 3.6 h 3.6±1.1 h Raceme D/L; The Pharmacological Basis of Therapeutics
Half-life 4.8 h 4.8 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 190.0 mg/kg 190.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 190.0 mg/kg 190.0 mg/kg PO, oral; mouse; T3DB
Eliminate Route 87.5 % 78-97 % Urinary excretion; PO, oral; immediate release formulation; DRUGBANK
Eliminate Route 2.0 % 1-3 % Faeces excretion; PO, oral; immediate release formulation; DRUGBANK
Eliminate Route 1.0 % <1 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 1.3 % 1.3±0.5 % Urinary excretion; Raceme D; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Eliminate Route 0.60 % 0.6±0.3 % Urinary excretion; Raceme D/L; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 15.0 % 15±5 % plasma proteins; DRUGBANK
Protein Binding 15.5 % 15-16 % Raceme D; Raceme D/L; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 85.0 mg/day 85 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 54.0 mg/day 54 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 60.0 mg/day 60 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 51.8 mg/day 51.8 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 100.0 mg/day 100 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 80.0 mg/day 30 mg/9-hour Transdermal preparations Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 30.0 mg/day 30 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for children 104.0 mg/day 104 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 85.0 mg/day 85 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 2.0 mg/kg/day 2 mg/kg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 72.0 mg/day 72 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 60.0 mg/day 60 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 51.8 mg/day 51.8 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 100.0 mg/day 100 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 0.138888888888889 mg/day 30 mg/9-hour Transdermal preparations Ritalin LA methylphenidate hydrochloride PDR
Max dose for adolescents 104.0 mg/day 104 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adults 100.0 mg/day 100 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adults 72.0 mg/day 72 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for adults 60.0 mg/day 60 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for geriatric 100.0 mg/day 100 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR
Max dose for geriatric 60.0 mg/day 60 mg/day PO, oral Ritalin LA methylphenidate hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1